Company intelligence / Profile preview

Psoriasis Research Institute of Guangzhou

Guangzhou, Guangdong, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 3

Overview

The institute has developed TC Cream, the world's first botanical small-molecule drug for psoriasis vulgaris. Phase IIb results (NCT03372811) demonstrated superior efficacy over vehicle control with excellent safety profile. Currently conducting multicenter Phase III trials in the U.S. through FDA IND clearance[1][2][5].

Therapeutic areas: Dermatology
Modalities: Botanical small molecules(TC Cream)
Industry: Biotech

Drug pipeline

1 asset

TC Cream

Phase 3

Indications: Psoriasis vulgaris

Partnerships

SUNY Downstate Medical Center (clinical trial site)[5]NCT03372811 clinical trial network sites

Beyond the preview

Go deeper on Psoriasis Research Institute of Guangzhou.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Psoriasis Research Institute of Guangzhou.

Explore the full profile